Top 3 Emerging Trends Impacting the Global Embolization Devices Market from 2017-2021: Technavio

Technavio has published a new report on the global embolization devices market from 2017-2021. (Graphic: Business Wire)

LONDON--()--Technavio’s latest report on the global embolization devices market provides an analysis on the most important trends expected to impact the market outlook from 2017-2021. Technavio defines an emerging trend as a factor that has the potential to significantly impact the market and contribute to its growth or decline.

The global embolization devices market is expected to grow rapidly during the forecast period because of the growing older population and increased prevalence of chronic diseases, such as cardiovascular diseases (CVDs) and cerebrovascular diseases. The growing awareness among people, rapid advances in technology and innovations, and growing product approvals are expected to propel the market growth in the future. In addition, rise in the cases of cardiac disorders will increase the number of diagnoses and cardiac surgeries. This increases the number of PCI procedures, which will increase the demand, sales, and use of EPDs.

This report is available at a USD 1,000 discount for a limited time only: View market snapshot before purchasing

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

The top three emerging trends driving the global embolization devices market according to Technavio healthcare and life science research analysts are:

  • New technological advancements
  • Growing surgeons' interest in adoption of flow diverters and neurovascular stents
  • Growing number of clinical trials

Looking for more information on this market? Request a free sample report

Technavio’s sample reports are free of charge and contain multiple sections of the report including the market size and forecast, drivers, challenges, trends, and more.

New technological advancements

“The penetration of neuroendovascular non-coil devices is low due to the limited product approvals in the market. However, the rapid technological advancements are leading to the increased adoption of these devices. There are a few products which are either in the development stage or have received regulatory approval only in one region. These products are highly advanced and are developed based on the preference of physicians,” says Srinivas Sashidar, a lead analyst at Technavio for research on cardiovascular devices.

Companies are entering the market with innovative technologies to gain high market shares. For instance, InspirMD is developing NVGuard with its proprietary MicroNet technology. The MicroNet platform provides superior clinical benefits and acts as a safety net to prevent debris flow in aneurysm patients.

Growing surgeons' interest in adoption of flow diverters and neurovascular stents

“There has been a dearth of skilled neurosurgeons in the market. The existing surgeons are focusing on the adoption of flow diverters for the treatment of brain aneurysm owing to their less invasive nature over other conventional methods, such as surgical clipping. Flow diversion aneurysm stenting is likely to become one of the widely accepted minimally invasive procedures for the treatment of intracranial aneurysm,” adds Srinivas.

The intracranial aneurysm treatment by flow diverters can only be conducted by neurosurgeons, interventional radiologists, or neurologists. Also, clinical studies have shown that a physician’s specialty may affect the use of invasive therapies. Physicians' acceptance of flow diverters globally has led to the increased use of other endovascular stents. This shows that aneurysm treatment using flow diverters is widely accepted among various medical professionals. Many hospitals and healthcare centers are recommending the procedure to individuals with carotid artery stenosis.

Growing number of clinical trials

The ongoing trials for non-coil technology in treating intracranial aneurysms have shown positive outcomes in addressing high recanalization rates when compared with other treatment procedures, such as coil embolization. However, more clinical evidence is required by surgeons for the safe and effective use non-coil techniques in treating intracranial aneurysms. As experience with flow diverters increase, the complication rates will reduce when compared with coil embolization.

Browse Related Reports:

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team at media@technavio.com.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 630 333 9501
UK: +44 208 123 1770
www.technavio.com

Release Summary

Technavio’s latest report on the global embolization devices market provides an analysis of the most important trends expected to impact the market

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 630 333 9501
UK: +44 208 123 1770
www.technavio.com